Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-08-06Clinical Trial Update: An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease [Phase 2, Phase 3]
A clinical trial update for lanabecestat in early Alzheimer's disease shows the study conduct with termination and posted results.
-
CLINICAL_TRIALS trial_result · 2019-08-06Clinical Trial Update: A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia [Phase 3]
Phase 3 trial of lanabecestat in mild Alzheimer's disease dementia terminated.
-
CLINICAL_TRIALS trial_result · 2019-08-05Clinical Trial Update: A Safety and Tolerability Study of GB301 [Phase 1, Phase 2]
A safety and tolerability study of GB301 in Alzheimer disease across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2019-07-31Clinical Trial Update: A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease [Phase 2, Phase 3]
Phase 2/3 trial evaluating albumin and immunoglobulin in Alzheimer's disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-07-30Clinical Trial Update: Endothelial Facilitation in Alzheimer's Disease [Phase 2]
A Phase 2 clinical trial on endothelial facilitation for Alzheimer's disease has been completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-07-23FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Nivagen Pharmaceuticals, Inc.)
FDA approved a supplemental application for rivastigmine tartrate from Nivagen Pharmaceuticals, Inc., enabling a generic rivastigmine tartra…
-
FDA approval · 2019-07-22FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for rivastigmine tartrate by Alembic Pharmaceuticals Limited, authorizing a generic rivastigmine tar…
-
CLINICAL_TRIALS trial_result · 2019-07-19Clinical Trial Update: A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease [Phase 1]
Phase 1 trial update for LY2886721 in healthy participants and individuals with Alzheimer disease; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2019-07-19Clinical Trial Update: A Safety Study of LY2886721 Multiple Doses in Healthy Subjects [Phase 1]
Phase 1 safety study of LY2886721 with multiple doses in healthy subjects completed; results posted.
-
FDA approval · 2019-07-16FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for a generic rivastigmine tartrate product from Dr. Reddy's Laboratories (ANDA). Rivastigmine tartr…
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia [Phase 3]
Phase 3 study of lanabecestat (LY3314814) in early Alzheimer's disease dementia was terminated with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-07-02Clinical Trial Update: Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) [Phase 2]
Phase 2 trial investigating levetiracetam for neuropsychiatric symptoms related to epilepsy in Alzheimer's disease patients; status not spec…
-
FDA approval · 2019-06-28FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for memantine hydrochloride from Macleods Pharmaceuticals Limited under the ANDA program, approving …
-
FDA approval · 2019-06-28FDA Approved: MEMANTINE — Supplemental Application (NorthStar RxLLC)
The FDA approved a supplemental application for memantine submitted by NorthStar RxLLC.
-
FDA approval · 2019-06-28FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for memantine hydrochloride, a generic form of memantine used to treat Alzheime…
-
FDA approval · 2019-06-28FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for memantine hydrochloride from Aurobindo Pharma Limited. The action updates the approved product u…
-
FDA approval · 2019-06-28FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Viona Pharmaceuticals Inc)
FDA approves a supplemental application for Memantine Hydrochloride from Viona Pharmaceuticals Inc.
-
FDA approval · 2019-06-28FDA Approved: MEMANTINE — Supplemental Application (Chartwell RX, LLC)
The FDA approved Chartwell RX LLC's supplemental application for memantine. This action approves a supplemental filing for a generic memanti…
-
FDA approval · 2019-06-28FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for memantine hydrochloride from Upsher-Smith Laboratories, LLC.
-
FDA approval · 2019-06-28FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved a supplemental application for memantine hydrochloride by Amneal Pharmaceuticals of New York LLC. The approval concerns a g…
-
CLINICAL_TRIALS trial_result · 2019-06-25Clinical Trial Update: Caring for the Caregiver Network [NA]
Clinical trial update for a caregiver support network study; completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-14Clinical Trial Update: A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD) [Phase 2]
Phase 2 clinical trial evaluating p38 MAP kinase inhibitor VX-745 on amyloid plaque load in Alzheimer's disease and mild cognitive impairmen…
-
CLINICAL_TRIALS trial_result · 2019-06-10Clinical Trial Update: Evaluating Liraglutide in Alzheimer's Disease [Phase 2]
Phase 2 clinical trial evaluating liraglutide for Alzheimer's disease is ongoing with unknown status.
-
CLINICAL_TRIALS trial_result · 2019-06-10Clinical Trial Update: Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants [Phase 1]
Phase 1 trial update for TAK-071 includes healthy participants and those with mild cognitive impairment/mild Alzheimer disease; study termin…
-
CLINICAL_TRIALS trial_result · 2019-06-04Clinical Trial Update: Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease [Phase 2]
A Phase 2 dose-finding study evaluated the efficacy and safety of ID1201 in patients with mild Alzheimer's disease and has completed.